论文部分内容阅读
用竞争性酶免疫分析法（EIA）测定了内分泌疾病患者空腹晨尿中骨吸收新标志吡啶并啉（Pyr）的浓度。结果显示：甲亢和甲状旁眼机能亢进（甲旁亢）患者治疗前尿Pyr浓度显著高于中青年对照组，治疗后均有显著下降；柯兴氏病组和绝经5年以上的骨质疏松患者尿Pyr浓度与中青年对照组没有明显差别。提示尿中游离Pyr能灵敏地反映内分泌疾病的破骨细胞活性变化，有助于分析其发生骨质疏松的机理。
The concentration of pyridoxine (Pyr), a new marker of bone resorption in fasting morning urine, was measured by competitive enzyme immunoassay (EIA) in patients with endocrine disorders. The results showed that urinary Pyr concentrations in patients with hyperthyroidism and hyperparathyroidism (hyperparathyroidism) before treatment were significantly higher than those in young and middle-aged patients, and both were significantly decreased after treatment. In Cushing’s disease group and those with more than 5 years after menopause Urinary Pyr concentration in patients with no significant difference between young and middle-aged control group. Tip Urine free Pyr can sensitively reflect changes in endocrine disease activity of osteoclasts, help to analyze the mechanism of its occurrence of osteoporosis.